Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD1916 vs Novo Nordisk semaglutide in type 2 diabetes mellitus
CTR20233923Phase 3Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Dec 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20233923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233923.